

aTAG 4531 Biochemical | aTAG4531 biochemical

aTAG 4531

CATALOG #
AAA227030


PRODUCT SYNONYMS

aTAG 4531; aTAG4531 biochemical

PRODUCT SPECIFICATIONS


Purity/Purification	98%
Solubility	DMSO: Soluble <1mg/ml refers to the product slightly soluble or insoluble
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure

7-Deaza-7-propargylamino-ddGTP, CAS 114748-61-7



Structure

7-Deaza-7-propargylamino-ddGTP, CAS 114748-61-7

ADDITIONAL INFORMATION

Related Product Information for aTAG4531 biochemical	Degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide. Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.34 nM; Dmax = 93.14%). Cell-permeable. Suitable for in vitro and in vivo applications. Mouse DMPK properties are provided in the supplementary file (see below). (MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in - see protocol for more information.)
References	1. Peng Peng, et al. A novel target enrichment strategy in next-generation sequencing through 7-deaza-dGTP-resistant enzymatic digestion. BMC Res Notes. 2020 Sep 18;13(1):445.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.